BRAIN and NERVE－神経研究の進歩73巻4号

2021年04月発行

特集 片頭痛・群発頭痛治療の新たな夜明け

CGRP関連抗体の片頭痛治療への応用

著者： 柴田護¹

所属機関： ¹東京歯科大学市川総合病院神経内科

ページ範囲：P.327 - P.337

文献概要

片頭痛は有病率が高く，個々の患者のQOLが大きく障害されることから，社会全体に与える経済的悪影響は甚大である。片頭痛は視床下部，大脳皮質，三叉神経系などの機能異常に基づく神経疾患である。従来の片頭痛発作予防治療薬は疾患特異的に開発されたものではなく，十分な効果が得られないことも多い。カルシトニン遺伝子関連ペプチド（CGRP）が片頭痛病態に深く関与することが明らかとなり，CGRP関連抗体による治療法が脚光を浴びている。

参考文献

1)GBD 2016 Disease and Injury Incidence and Prevalence Collaborators: Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 390: 1211-1259, 2017

2)坂井文彦: 頭痛の診療システム（頭痛専門医制度, 頭痛専門外来, 医療連携）. 治療93: 1609-1613, 2011

3)Parikh SK, Young WB: Migraine: stigma in society. Curr Pain Headache Rep 23: 8, 2019［doi: 10.1007/s11916-019-0743-7］

4)Amara SG, Jonas V, Rosenfeld MG, Ong ES, Evans RM: Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products. Nature 298: 240-244, 1982

5)Alevizaki M, Shiraishi A, Rassool FV, Ferrier GJ, MacIntyre I, et al: The calcitonin-like sequence of the beta CGRP gene. FEBS Lett 206: 47-52, 1986

6)Rosenfeld MG, Mermod JJ, Amara SG, Swanson LW, Sawchenko PE, et al: Production of a novel neuropeptide encoded by the calcitonin gene via tissue-specific RNA processing. Nature 304: 129-135, 1983

7)Mason RT, Peterfreund RA, Sawchenko PE, Corrigan AZ, Rivier JE, et al: Release of the predicted calcitonin gene-related peptide from cultured rat trigeminal ganglion cells. Nature 308: 653-655, 1984

8)Walker CS, Conner AC, Poyner DR, Hay DL: Regulation of signal transduction by calcitonin gene-related peptide receptors. Trends Pharmacol Sci 31: 476-483, 2010

9)Liang YL, Khoshouei M, Deganutti G, Glukhova A, Koole C, et al: Cryo-EM structure of the active, Gs-protein complexed, human CGRP receptor. Nature 561: 492-497, 2018

10)Luebke AE, Dahl GP, Roos BA, Dickerson IM: Identification of a protein that confers calcitonin gene-related peptide responsiveness to oocytes by using a cystic fibrosis transmembrane conductance regulator assay. Proc Natl Acad Sci U S A 93: 3455-3460, 1996

11)Han JS, Li W, Neugebauer V: Critical role of calcitonin gene-related peptide 1 receptors in the amygdala in synaptic plasticity and pain behavior. J Neurosci 25: 10717-10728, 2005

12)Okutsu Y, Takahashi Y, Nagase M, Shinohara K, Ikeda R, et al: Potentiation of NMDA receptor-mediated synaptic transmission at the parabrachial-central amygdala synapses by CGRP in mice. Mol Pain 13: 1744806917709201, 2017［doi: 10.1177/1744806917709201］

13)Zeller J, Poulsen KT, Sutton JE, Abdiche YN, Collier S, et al: CGRP function-blocking antibodies inhibit neurogenic vasodilatation without affecting heart rate or arterial blood pressure in the rat. Br J Pharmacol 155: 1093-1103, 2008

14)Cottrell GS, Alemi F, Kirkland JG, Grady EF, Corvera CU, et al: Localization of calcitonin receptor-like receptor (CLR) and receptor activity-modifying protein 1 (RAMP1) in human gastrointestinal tract. Peptides 35: 202-211, 2012

15)Falkenberg K, Bjerg HR, Olesen J: Two-hour CGRP infusion causes gastrointestinal hyperactivity: possible relevance for CGRP antibody treatment. Headache 60: 929-937, 2020

16)Bernstein C, Burstein R: Sensitization of the trigeminovascular pathway: perspective and implications to migraine pathophysiology. J Clin Neurol 8: 89-99, 2012

17)Iyengar S, Ossipov MH, Johnson KW: The role of calcitonin gene-related peptide in peripheral and central pain mechanisms including migraine. Pain 158: 543-559, 2017

18)Edvinsson L, Haanes KA, Warfvinge K, Krause DN: CGRP as the target of new migraine therapies - successful translation from bench to clinic. Nat Rev Neurol 14: 338-350, 2018

19)Shimizu T, Shibata M, Toriumi H, Iwashita T, Funakubo M, et al: Reduction of TRPV1 expression in the trigeminal system by botulinum neurotoxin type-A. Neurobiol Dis 48: 367-378, 2012

20)Melo-Carrillo A, Strassman AM, Nir RR, Schain AJ, Noseda R, et al: Fremanezumab: a humanized monoclonal anti-CGRP antibody: inhibits thinly myelinated (Aδ) but not unmyelinated (C) meningeal nociceptors. J Neurosci 37: 10587-10596, 2017

21)Shibata M, Tang C: Implications of transient receptor potential cation channels in migraine pathophysiology. Neurosci Bull, 2020 [Online ahead of print]［doi: 10.1007/s12264-020-00569-5］

22)Edvinsson JCA, Warfvinge K, Krause DN, Blixt FW, Sheykhzade M, et al: C-fibers may modulate adjacent Aδ-fibers through axon-axon CGRP signaling at nodes of Ranvier in the trigeminal system. J Headache Pain 20: 105, 2019［doi: 10.1186/s10194-019-1055-3］

23)Olesen J, Burstein R, Ashina M, Tfelt-Hansen P: Origin of pain in migraine: evidence for peripheral sensitisation. Lancet Neurol 8: 679-690, 2009

24)Burstein R, Jakubowski M, Garcia-Nicas E, Kainz V, Bajwa Z, et al: Thalamic sensitization transforms localized pain into widespread allodynia. Ann Neurol 68: 81-91, 2010

25)Kato F, Sugimura YK, Takahashi Y: Pain-associated neural plasticity in the parabrachial to central amygdala circuit: pain changes the brain, and the brain changes the pain. Adv Exp Med Biol 1099: 157-166, 2018

26)Malick A, Strassman RM, Burstein R: Trigeminohypothalamic and reticulohypothalamic tract neurons in the upper cervical spinal cord and caudal medulla of the rat. J Neurophysiol 84: 2078-2112, 2000

27)Benarroch EE: CGRP: sensory neuropeptide with multiple neurologic implications. Neurology 77: 281-287, 2011

28)Warfvinge K, Edvinsson L: Distribution of CGRP and CGRP receptor components in the rat brain. Cephalalgia 39: 342-353, 2019

29)Maniyar FH, Sprenger T, Monteith T, Schankin C, Goadsby PJ: Brain activations in the premonitory phase of nitroglycerin-triggered migraine attacks. Brain 137: 232-241, 2014

30)Schulte LH, May A: The migraine generator revisited: continuous scanning of the migraine cycle over 30 days and three spontaneous attacks. Brain 139: 1987-1993, 2016

31)Ayata C, Lauritzen M: Spreading depression, spreading depolarizations, and the cerebral vasculature. Physiol Rev 95: 953-993, 2015

32)Tozzi A, de Iure A, di Filippo M, Costa C, Caproni S, et al: Critical role of calcitonin gene-related peptide receptors in cortical spreading depression. Proc Natl Acad Sci U S A 109: 18985-18990, 2012

33)Zagami AS, Goadsby PJ, Edvinsson L: Stimulation of the superior sagittal sinus in the cat causes release of vasoactive peptides. Neuropeptides 16: 69-75, 1990

34)Goadsby PJ, Edvinsson L, Ekman R: Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 28: 183-187, 1990

35)Tvedskov JF, Lipka K, Ashina M, Iversen HK, Schifter S, et al: No increase of calcitonin gene-related peptide in jugular blood during migraine. Ann Neurol 58: 561-568, 2005

36)Cernuda-Morollón E, Larrosa D, Ramón C, Vega J, Martínez-Camblor P, et al: Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine. Neurology 81: 1191-1196, 2013

37)Greco R, de Icco R, Demartini C, Zanaboni AM, Tumelero E, et al: Plasma levels of CGRP and expression of specific microRNAs in blood cells of episodic and chronic migraine subjects: towards the identification of a panel of peripheral biomarkers of migraine? J Headache Pain 21: 122, 2020［doi: 10.1186/s10194-020-01189-0］

38)Lassen LH, Haderslev PA, Jacobsen VB, Iversen HK, Sperling B, et al: CGRP may play a causative role in migraine. Cephalalgia 22: 54-61, 2002

39)Hansen JM, Hauge AW, Olesen J, Ashina M: Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura. Cephalalgia 30: 1179-1186, 2010

40)Messlinger K: The big CGRP flood: sources, sinks and signalling sites in the trigeminovascular system. J Headache Pain 19: 22, 2018［doi: 10.1186/s10194-018-0848-0］

41)Dodick DW: CGRP ligand and receptor monoclonal antibodies for migraine prevention: evidence review and clinical implications. Cephalalgia 39: 445-458, 2019

42)Foltz IN, Karow M, Wasserman SM: Evolution and emergence of therapeutic monoclonal antibodies: what cardiologists need to know. Circulation 127: 2222-2230, 2013

43)Garces F, Mohr C, Zhang L, Huang CS, Chen Q, et al: Molecular insight into recognition of the CGRPR complex by migraine prevention therapy aimovig (erenumab). Cell Rep 30: 1714-1723. e6, 2020［doi: 10.1016/j.celrep.2020.01.029］

44)Vidarsson G, Dekkers G, Rispens T: IgG subclasses and allotypes: from structure to effector functions. Front Immunol 5: 520, 2014［doi: 10.3389/fimmu.2014.00520］

45)Stauffer VL, Dodick DW, Zhang Q, Carter JN, Ailani J, et al: Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA Neurol 75: 1080-1088, 2018

46)Skljarevski V, Matharu M, Millen BA, Ossipov MH, Kim BK, et al: Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 Phase 3 randomized controlled clinical trial. Cephalalgia 38: 1442-1454, 2018

47)Detke HC, Millen BA, Zhang Q, Samaan K, Ailani J, et al: Rapid onset of effect of galcanezumab for the prevention of episodic migraine: analysis of the EVOLVE studies. Headache 60: 348-359, 2020

48)Förderreuther S, Zhang Q, Stauffer VL, Aurora SK, Láinez MJA: Preventive effects of galcanezumab in adult patients with episodic or chronic migraine are persistent: data from the phase 3, randomized, double-blind, placebo-controlled EVOLVE-1, EVOLVE-2, and REGAIN studies. J Headache Pain 19: 121, 2018［doi: 10.1186/s10194-018-0951-2］

49)Oakes TM, Kovacs R, Rosen N, Doty E, Kemmer P, et al: Evaluation of cardiovascular outcomes in adult patients with episodic or chronic migraine treated with galcanezumab: data from three phase 3, randomized, double-blind, placebo-controlled EVOLVE-1, EVOLVE-2, and REGAIN studies. Headache 60: 110-123, 2020

50)Dodick DW, Doty EG, Aurora SK, Ruff DD, Stauffer VL, et al: Medication overuse in a subgroup analysis of phase 3 placebo-controlled studies of galcanezumab in the prevention of episodic and chronic migraine. Cephalalgia: 333102420966658, 2020 [Online ahead of print]［doi: 10.1177/0333102420966658］

51)Dodick DW, Silberstein SD, Bigal ME, Yeung PP, Goadsby PJ, et al: Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial. JAMA 319: 1999-2008, 2018

52)Silberstein SD, Dodick DW, Bigal ME, Yeung PP, Goadsby PJ, et al: Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med 377: 2113-2122, 2017

53)Winner PK, Spierings ELH, Yeung PP, Aycardi E, Blankenbiller T, et al: Early onset of efficacy with fremanezumab for the preventive treatment of chronic migraine. Headache 59: 1743-1752, 2019

54)VanderPluym J, Dodick DW, Lipton RB, Ma Y, Loupe PS, et al: Fremanezumab for preventive treatment of migraine: functional status on headache-free days. Neurology 91: e1152-e1165, 2018［doi: 10.1212/01.wnl.0000544321.19316.40］

55)Goadsby PJ, Reuter U, Hallström Y, Broessner G, Bonner JH, et al: A controlled trial of erenumab for episodic migraine. N Engl J Med 377: 2123-2132, 2017

56)Goadsby PJ, Reuter U, Hallström Y, Broessner G, Bonner JH, et al: One-year sustained efficacy of erenumab in episodic migraine: Results of the STRIVE study. Neurology 95: e469-e479, 2020［doi: 10.1212/WNL.0000000000010019］

57)Dodick DW, Ashina M, Brandes JL, Kudrow D, Lanteri-Minet M, et al: ARISE: A Phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia 38: 1026-1037, 2018

58)Sakai F, Takeshima T, Tatsuoka Y, Hirata K, Lenz R, et al: A randomized phase 2 study of erenumab for the prevention of episodic migraine in Japanese adults. Headache 59: 1731-1742, 2019

59)Tepper SJ, Diener HC, Ashina M, Brandes JL, Friedman DI, et al: Erenumab in chronic migraine with medication overuse: subgroup analysis of a randomized trial. Neurology 92: e2309-e2320, 2019［doi: 10.1212/WNL.0000000000007497］

60)Scheffler A, Messel O, Wurthmann S, Nsaka M, Kleinschnitz C, et al: Erenumab in highly therapy-refractory migraine patients: first German real-world evidence. J Headache Pain 21: 84, 2020［doi: 10.1186/s10194-020-01151-0］

61)Ornello R, Casalena A, Frattale I, Caponnetto V, Gabriele A, et al: Conversion from chronic to episodic migraine in patients treated with erenumab: real-life data from an Italian region. J Headache Pain 21: 102, 2020［doi: 10.1186/s10194-020-01171-w］

62)Schwedt T, Reuter U, Tepper S, Ashina M, Kudrow D, et al: Early onset of efficacy with erenumab in patients with episodic and chronic migraine. J Headache Pain 19: 92, 2018［doi: 10.1186/s10194-018-0923-6］

63)Buse DC, Lipton RB, Hallström Y, Reuter U, Tepper SJ, et al: Migraine-related disability, impact, and health-related quality of life among patients with episodic migraine receiving preventive treatment with erenumab. Cephalalgia 38: 1622-1631, 2018

64)Mullin K, Kudrow D, Croop R, Lovegren M, Conway CM, et al: Potential for treatment benefit of small molecule CGRP receptor antagonist plus monoclonal antibody in migraine therapy. Neurology 94: e2121-e2125, 2020［doi: 10.1212/WNL.0000000000008944］

65)Ashina M, Goadsby PJ, Reuter U, Silberstein S, Dodick D, et al: Long-term safety and tolerability of erenumab: three-plus year results from a five-year open-label extension study in episodic migraine. Cephalalgia 39: 1455-1464, 2019

66)Kudrow D, Pascual J, Winner PK, Dodick DW, Tepper SJ, et al: Vascular safety of erenumab for migraine prevention. Neurology 94: e497-e510, 2020［doi: 10.1212/WNL.0000000000008743］

67)Robblee J, Devick KL, Mendez N, Potter J, Slonaker J, et al: Real-world patient experience with erenumab for the preventive treatment of migraine. Headache 60: 2014-2025, 2020

68)Kanaan S, Hettie G, Loder E, Burch R: Real-world effectiveness and tolerability of erenumab: a retrospective cohort study. Cephalalgia 40: 1511-1522, 2020

69)U.S. Food and Drug Administration: Drug Safety-related Labeling Changes (SrLC). https://www.accessdata.fda.gov/scripts/cder/safetylabelingchanges/index.cfm?event=searchdetail.page＆DrugNameID=1894（最終閲覧日: 2021年1月27日）

70)Ashina M, Saper J, Cady R, Schaeffler BA, Biondi DM, et al: Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia 40: 241-254, 2020

71)Lipton RB, Goadsby PJ, Smith J, Schaeffler BA, Biondi DM, et al: Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2. Neurology 94: e1365-e1377, 2020［doi: 10.1212/WNL.0000000000009169］

72)Dodick DW, Gottschalk C, Cady R, Hirman J, Smith J, et al: Eptinezumab demonstrated efficacy in sustained prevention of episodic and chronic migraine beginning on day 1 after dosing. Headache 60: 2220-2231, 2020

73)Ruff DD, Ford JH, Tockhorn-Heidenreich A, Stauffer VL, Govindan S, et al: Efficacy of galcanezumab in patients with episodic migraine and a history of preventive treatment failure: results from two global randomized clinical trials. Eur J Neurol 27: 609-618, 2020

74)Mulleners WM, Kim BK, Lainez MJA, Lanteri-Minet M, Pozo-Rosich P, et al: Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol 19: 814-825, 2020

75)Reuter U, Goadsby PJ, Lanteri-Minet M, Wen S, Hours-Zesiger P, et al: Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet 392: 2280-2287, 2018

76)Ferrari MD, Diener HC, Ning X, Galic M, Cohen JM, et al: Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. Lancet 394: 1030-1040, 2019

77)Gangula PR, Zhao H, Supowit SC, Wimalawansa SJ, Dipette DJ, et al: Increased blood pressure in alpha-calcitonin gene-related peptide/calcitonin gene knockout mice. Hypertension 35: 470-475, 2000

78)Oh-hashi Y, Shindo T, Kurihara Y, Imai T, Wang Y, et al: Elevated sympathetic nervous activity in mice deficient in alphaCGRP. Circ Res 89: 983-990, 2001

79)Mai TH, Wu J, Diedrich A, Garland EM, Robertson D: Calcitonin gene-related peptide (CGRP) in autonomic cardiovascular regulation and vascular structure. J Am Soc Hypertens 8: 286-296, 2014

80)Smillie SJ, King R, Kodji X, Outzen E, Pozsgai G, et al: An ongoing role of α-calcitonin gene-related peptide as part of a protective network against hypertension, vascular hypertrophy, and oxidative stress. Hypertension 63: 1056-1062, 2014

81)Mikami N, Miyagi Y, Sueda K, Takatsuji M, Fukada S, et al: Calcitonin gene-related peptide and cyclic adenosine 5'-monophosphate/protein kinase A pathway promote IL-9 production in Th9 differentiation process. J Immunol 190: 4046-4055, 2013

82)Wallrapp A, Burkett PR, Riesenfeld SJ, Kim SJ, Christian E, et al: Calcitonin gene-related peptide negatively regulates alarmin-driven type 2 innate lymphoid cell responses. Immunity 51: 709-723, 2019

83)Mulder IA, Li M, de Vries T, Qin T, Yanagisawa T, et al: Anti-migraine calcitonin gene-related peptide receptor antagonists worsen cerebral ischemic outcome in mice. Ann Neurol 88: 771-784, 2020

84)Zhai L, Sakurai T, Kamiyoshi A, Ichikawa-Shindo Y, Kawate H, et al: Endogenous calcitonin gene-related peptide suppresses ischemic brain injuries and progression of cognitive decline. J Hypertens 36: 876-891, 2018

85)Pinho-Ribeiro FA, Baddal B, Haarsma R, O'Seaghdha M, Yang NJ, et al: Blocking neuronal signaling to immune cells treats streptococcal invasive infection. Cell 173: 1083-1097, 2018

86)Toriyama Y, Iesato Y, Imai A, Sakurai T, Kamiyoshi A, et al: Pathophysiological function of endogenous calcitonin gene-related peptide in ocular vascular diseases. Am J Pathol 185: 1783-1794, 2015